Drugs / MSP3 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00469651 | Oct 2007 → Aug 2008 | malaria | African Malaria Network Trust | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSP3 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00469651 ↗ |
| Known as | Merozoite Surface Protein-3 | “A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has been shown to be safe in non-immune and semi-immune adults.” PMID 19607731 ↗ Jul 2009 |
| Modality | Vaccine | “A blood stage malaria vaccine candidate” PMID 19607731 ↗ Jul 2009 |
| Route | Subcutaneous | “The study vaccine will be administered through the subcutaneous injection into right or left deltoid (alternately).” NCT00469651 ↗ |